The Possible Role of Kallikrein-6, 7, and Potassium Channel Proteins in Alzheimer’s Disease

dc.authorscopusid56394439600
dc.authorscopusid36919893100
dc.authorscopusid16403754400
dc.contributor.authorBulduk, Erkut Baha
dc.contributor.authorYildirim,F.
dc.contributor.authorYildirim,Z.
dc.contributor.otherSurgical Sciences
dc.date.accessioned2024-07-05T15:46:05Z
dc.date.available2024-07-05T15:46:05Z
dc.date.issued2021
dc.departmentAtılım Universityen_US
dc.department-tempBulduk E.B., Atılım University, Faculty of Medicine, Department of Neurosurgery, Ankara, Turkey; Yildirim F., Polatlı Duatepe Government Hospital, Clinic of Internal Medicine, Ankara, Turkey; Yildirim Z., Ankara Health Directorate, Public Health Services Presidency, Ankara, Turkeyen_US
dc.description.abstractObjective: Although the formation mechanism of Alzheimer’s Disease (AD) is not known with certainty, two major proteins, beta amyloid of senile plaques and tau protein of neurofibrillary tangels are responsible for AD. One of the major factors in the development of the disease is the formation of in soluble amyloid deposits, and the other one is the increased tau phosphorylation. Kallikreins (KLK’s) are a sub-family of serine proteases that play a role in the etiology of AD which is characterized by neuronal damage and loss of function.Kallikrein (KLK)-6 and KLK-7 are known to be age-related protease and are found at high levels in the central nervous system (CNS). It was previously shown to be involved in proteolysis of extracellular proteins implicated in neurodegenerative diseases such as AD. In this study, we aimed to investigate the possible role of KLK-6 and KLK-7 in the pathogenesis of AD and the relationship between potassium channel proteins. Methods: A total of 35 Alzheimer’s patients over the age 65 years, followed-up by Polatlı Duatepe Government Hospital and 35 healthy individuals (control group) admitted to the neurology clinic for routine screening with cognitive status considered normal were included in this study. After a 12-hour hunger, KLK-6 and KLK-7 were measured with inwardly rectifying potassium channel protein (KCNJ3), and two-pore potassium channel protein (KCNK9) levels were measured by the Enzyme-Linked Immuno Sorbent Assay (ELISA) in the serum of the blood samples which were taken from the antecubital vein after centrifuging for 10 minutes at 2500xg. The differences between the two groups were tested by T- test. A value of p<0.05 was considered statistically significant. Results: All the groups were matched for age and gender, but not statistically significant difference was observed (p>0.05). According to our findings, serum KLK- 6 and KLK-7 levels of Alzheimer’s group were significantly increased (p<0.05). A significant difference was not detected when the levels of serum KCNJ3 and KCNK9 of the Alzheimer’s group compared with the control group (p>0.05). Conclusion: It is thought that the failure in preventing the abnormal protein folding and accumulation leads to AD in the brain. According to the findings of the present study, a positive correlation was detected between the levels of KLK-6 and KLK-7 and AD’s pathology. © 2021. All Rights Reserved.en_US
dc.identifier.citation0
dc.identifier.doi10.5505/TurkHijyen.2020.50374
dc.identifier.endpage132en_US
dc.identifier.issn0377-9777
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85110451309
dc.identifier.startpage125en_US
dc.identifier.urihttps://doi.org/10.5505/TurkHijyen.2020.50374
dc.identifier.urihttps://hdl.handle.net/20.500.14411/4014
dc.identifier.volume78en_US
dc.language.isoenen_US
dc.publisherRefik Saydam National Public Health Agency (RSNPHA)en_US
dc.relation.ispartofTurk Hijyen ve Deneysel Biyoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlzheimer’s diseaseen_US
dc.subjectKallikrein-6en_US
dc.subjectKallikrein-7en_US
dc.subjectKCNJ3en_US
dc.subjectKCNK9en_US
dc.titleThe Possible Role of Kallikrein-6, 7, and Potassium Channel Proteins in Alzheimer’s Diseaseen_US
dc.typeArticleen_US
dspace.entity.typePublication
relation.isAuthorOfPublication191c8fb9-afd9-4502-b067-67e2b70fd0e9
relation.isAuthorOfPublication.latestForDiscovery191c8fb9-afd9-4502-b067-67e2b70fd0e9
relation.isOrgUnitOfPublicationa496aaf0-0817-4258-97e0-1fbdc4cc0841
relation.isOrgUnitOfPublication.latestForDiscoverya496aaf0-0817-4258-97e0-1fbdc4cc0841

Files

Collections